NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) |
|
|
| Recruiting | 2 | 60 | Europe, US, RoW | Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Ovarian Cancer | 01/28 | 01/28 | | |
